FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and relates to an anti-PRLR antibody preparation for non-hormonal treatment of endometriosis containing histidine, a non-ionic surfactant, saccharum selected from mannitol, dextrose, glucose, trehalose and sucrose, arginine, methionine, anti-PRLR antibody. Where said anti-PRLR antibody preparation has pH that ranges from pH 5.0 to pH 6.5, where said anti-PRLR preparation is substantially free from an inorganic salt, and where said anti-PRLR antibody is a human IgG2 monoclonal antibody. Group of inventions also concerns the use of this anti-PRLR antibody preparation for non-hormonal treatment of endometriosis.
EFFECT: group of inventions provides the creation of preparations with a high concentration of antibodies to the anti-prolactin receptor, which, at that, are actually iso-osmotic and have a low viscosity.
17 cl, 6 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY AND PROTEIN COMPOSITIONS | 2013 |
|
RU2678097C2 |
ANTIBODY FORMULATIONS | 2012 |
|
RU2665810C2 |
FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
COMPOSITIONS OF ANTIBODIES TO RSV AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2807524C2 |
COMPOSITIONS CONTAINING ANTIBODY-DRUG CONJUGATES DUOCARMICIN | 2016 |
|
RU2687237C1 |
METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES | 2014 |
|
RU2671481C2 |
ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
STABLE AQUEOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY COMPOSITION | 2016 |
|
RU2699544C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
Authors
Dates
2018-04-02—Published
2013-08-28—Filed